The virtual biopsy market size has grown rapidly in recent years. It will grow from $0.71 billion in 2025 to $0.79 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to reliance on traditional biopsy procedures, limited imaging technology capabilities, increasing prevalence of chronic diseases, growing hospital and diagnostic infrastructure, rising demand for accurate cancer diagnostics.
The virtual biopsy market size is expected to see rapid growth in the next few years. It will grow to $1.23 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to advancements in imaging algorithms and ai analytics, expansion of oncology and neurological diagnostic applications, increasing adoption in cardiovascular and ophthalmological disorders, integration with personalized medicine approaches, rising investment in research institutes and diagnostic centers. Major trends in the forecast period include increased adoption of non-invasive diagnostic procedures, rising demand for early disease detection, integration of advanced imaging with predictive analytics, expansion of virtual biopsy applications across multiple therapeutic areas, growing focus on patient comfort and reduced recovery time.
The rising prevalence of oncological disorders is expected to drive the growth of the virtual biopsy market in the coming years. Oncological disorders are health conditions related to cancer, characterized by the abnormal growth and spread of cells in the body. The increasing prevalence of these disorders is largely attributed to lifestyle factors such as poor diet, physical inactivity, tobacco use, and greater exposure to environmental pollutants. Virtual biopsy enhances the diagnosis and monitoring of oncological disorders by providing non-invasive, real-time imaging insights, reducing reliance on traditional tissue biopsies while improving accuracy and patient safety. For example, in January 2023, Rock Health, a U.S.-based digital health research firm, reported that 1,958,310 new cancer cases were projected in the U.S. for 2023, up from approximately 1.9 million cases in 2022. Therefore, the rising prevalence of oncological disorders is driving the virtual biopsy market.
The growing demand for telemedicine is also expected to propel the virtual biopsy market. Telemedicine refers to the remote delivery of healthcare services using digital communication technologies, including video conferencing, mobile applications, and telecommunication networks. The increasing adoption of telemedicine is driven by improved healthcare accessibility, cost efficiency, and advancements in digital health technologies. Virtual biopsy supports telemedicine by enabling remote, non-invasive tissue assessment through advanced imaging and AI-powered analysis, allowing clinicians to monitor and diagnose patients without in-person visits, thereby enhancing accessibility and continuity of care. For instance, in July 2023, Harmony Healthcare IT, a US-based data management firm, reported that 62% of Americans had used telehealth services for medical needs, with over three-quarters (77%) viewing it as the future of healthcare. Therefore, the rising demand for telemedicine is driving the growth of the virtual biopsy market.
Major companies in the virtual biopsy market are focusing on developing technologically advanced solutions and obtaining regulatory approvals, such as magnetic resonance spectroscopy (MRS) platforms, to enhance non-invasive diagnostic accuracy and provide real-time analysis for early disease detection and personalized treatment. Magnetic resonance spectroscopy (MRS) is a non-invasive imaging technique that enables virtual biopsy by providing detailed molecular information of tissues, allowing accurate, real-time disease detection and monitoring without invasive procedures. For example, in November 2023, BrainSpec Inc., a US-based healthtech company, received approval from the U.S. Food and Drug Administration (FDA) for its AI-driven BrainSpec platform. This technology applies advanced artificial intelligence analysis to MR spectroscopy data to measure brain metabolites such as 2-hydroxyglutarate, facilitating non-invasive virtual biopsies for conditions including gliomas, Alzheimer’s disease, and multiple sclerosis. The system integrates seamlessly with standard MRI scanners, automates data processing, delivers results within minutes, and leverages a reference database of brain chemistry to improve diagnostic accuracy.
Major companies operating in the virtual biopsy market are Siemens Healthineers AG, GE Healthcare, Canon Medical Systems, Philips Healthcare, Fujifilm Healthcare, Esaote SpA, Samsung Medison, Perspectum Ltd, QUIBIM SL, ImageBiopsy Lab GmbH, Deep Bio Inc, BrainSpec Inc, Oncoustics Inc, AI Metrics LLC, Zebra Medical Vision, Arterys Inc, Aidoc Medical, Viz ai, Subtle Medical, Gleamer AI.
North America was the largest region in the virtual biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the virtual biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the virtual biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the virtual biopsy market by increasing the cost of importing advanced imaging equipment, software platforms, and diagnostic tools. Segments such as magnetic resonance imaging and computed tomography devices are most impacted, particularly in Asia-Pacific regions including China and India. While tariffs have raised production and operational costs, they also encourage local manufacturing, foster innovation in cost-effective imaging solutions, and promote the development of domestic diagnostic technology capabilities.
The virtual biopsy market research report is one of a series of new reports that provides virtual biopsy market statistics, including virtual biopsy industry global market size, regional shares, competitors with a virtual biopsy market share, detailed virtual biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the virtual biopsy industry. This virtual biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Virtual biopsy is a non-invasive diagnostic method that leverages advanced imaging technologies and computer algorithms to analyze tissues for signs of disease. Its primary goal is to identify abnormalities, such as tumors or infections, without the need for traditional tissue sampling, minimizing risks and recovery time for patients. This technique is safer, faster, and less painful compared to conventional biopsies.
The main therapeutic areas targeted by virtual biopsy include oncology, neurology, cardiology, ophthalmology, endocrinology, gastroenterology, and other related conditions. Oncological disorders involve diseases characterized by the uncontrolled growth and spread of abnormal cells, commonly known as cancer, which can affect various organs and tissues. Virtual biopsy is used for detecting a wide range of cancers, including solid tumors, breast cancer, lung cancer, prostate cancer, colorectal cancer, brain cancer, and others. The imaging technologies utilized in virtual biopsy include magnetic resonance imaging (MRI), computed tomography (CT), X-ray, ultrasound, among others, and are employed by end users such as hospitals, clinics, research institutes, diagnostic centers, and more.
The virtual biopsy market consists of revenues earned by entities by providing services such as imaging diagnostics, artificial intelligence (AI)-based interpretation, biomarker testing, telemedicine services, and three-dimensional (3D) tissue modeling. The market value includes the value of related goods sold by the service provider or included within the service offering. The virtual biopsy market also includes sales of biopsy needle systems, artificial intelligence (AI)-based diagnostic tools, endoscopic systems, and photoacoustic imaging devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The virtual biopsy market size is expected to see rapid growth in the next few years. It will grow to $1.23 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to advancements in imaging algorithms and ai analytics, expansion of oncology and neurological diagnostic applications, increasing adoption in cardiovascular and ophthalmological disorders, integration with personalized medicine approaches, rising investment in research institutes and diagnostic centers. Major trends in the forecast period include increased adoption of non-invasive diagnostic procedures, rising demand for early disease detection, integration of advanced imaging with predictive analytics, expansion of virtual biopsy applications across multiple therapeutic areas, growing focus on patient comfort and reduced recovery time.
The rising prevalence of oncological disorders is expected to drive the growth of the virtual biopsy market in the coming years. Oncological disorders are health conditions related to cancer, characterized by the abnormal growth and spread of cells in the body. The increasing prevalence of these disorders is largely attributed to lifestyle factors such as poor diet, physical inactivity, tobacco use, and greater exposure to environmental pollutants. Virtual biopsy enhances the diagnosis and monitoring of oncological disorders by providing non-invasive, real-time imaging insights, reducing reliance on traditional tissue biopsies while improving accuracy and patient safety. For example, in January 2023, Rock Health, a U.S.-based digital health research firm, reported that 1,958,310 new cancer cases were projected in the U.S. for 2023, up from approximately 1.9 million cases in 2022. Therefore, the rising prevalence of oncological disorders is driving the virtual biopsy market.
The growing demand for telemedicine is also expected to propel the virtual biopsy market. Telemedicine refers to the remote delivery of healthcare services using digital communication technologies, including video conferencing, mobile applications, and telecommunication networks. The increasing adoption of telemedicine is driven by improved healthcare accessibility, cost efficiency, and advancements in digital health technologies. Virtual biopsy supports telemedicine by enabling remote, non-invasive tissue assessment through advanced imaging and AI-powered analysis, allowing clinicians to monitor and diagnose patients without in-person visits, thereby enhancing accessibility and continuity of care. For instance, in July 2023, Harmony Healthcare IT, a US-based data management firm, reported that 62% of Americans had used telehealth services for medical needs, with over three-quarters (77%) viewing it as the future of healthcare. Therefore, the rising demand for telemedicine is driving the growth of the virtual biopsy market.
Major companies in the virtual biopsy market are focusing on developing technologically advanced solutions and obtaining regulatory approvals, such as magnetic resonance spectroscopy (MRS) platforms, to enhance non-invasive diagnostic accuracy and provide real-time analysis for early disease detection and personalized treatment. Magnetic resonance spectroscopy (MRS) is a non-invasive imaging technique that enables virtual biopsy by providing detailed molecular information of tissues, allowing accurate, real-time disease detection and monitoring without invasive procedures. For example, in November 2023, BrainSpec Inc., a US-based healthtech company, received approval from the U.S. Food and Drug Administration (FDA) for its AI-driven BrainSpec platform. This technology applies advanced artificial intelligence analysis to MR spectroscopy data to measure brain metabolites such as 2-hydroxyglutarate, facilitating non-invasive virtual biopsies for conditions including gliomas, Alzheimer’s disease, and multiple sclerosis. The system integrates seamlessly with standard MRI scanners, automates data processing, delivers results within minutes, and leverages a reference database of brain chemistry to improve diagnostic accuracy.
Major companies operating in the virtual biopsy market are Siemens Healthineers AG, GE Healthcare, Canon Medical Systems, Philips Healthcare, Fujifilm Healthcare, Esaote SpA, Samsung Medison, Perspectum Ltd, QUIBIM SL, ImageBiopsy Lab GmbH, Deep Bio Inc, BrainSpec Inc, Oncoustics Inc, AI Metrics LLC, Zebra Medical Vision, Arterys Inc, Aidoc Medical, Viz ai, Subtle Medical, Gleamer AI.
North America was the largest region in the virtual biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the virtual biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the virtual biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the virtual biopsy market by increasing the cost of importing advanced imaging equipment, software platforms, and diagnostic tools. Segments such as magnetic resonance imaging and computed tomography devices are most impacted, particularly in Asia-Pacific regions including China and India. While tariffs have raised production and operational costs, they also encourage local manufacturing, foster innovation in cost-effective imaging solutions, and promote the development of domestic diagnostic technology capabilities.
The virtual biopsy market research report is one of a series of new reports that provides virtual biopsy market statistics, including virtual biopsy industry global market size, regional shares, competitors with a virtual biopsy market share, detailed virtual biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the virtual biopsy industry. This virtual biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Virtual biopsy is a non-invasive diagnostic method that leverages advanced imaging technologies and computer algorithms to analyze tissues for signs of disease. Its primary goal is to identify abnormalities, such as tumors or infections, without the need for traditional tissue sampling, minimizing risks and recovery time for patients. This technique is safer, faster, and less painful compared to conventional biopsies.
The main therapeutic areas targeted by virtual biopsy include oncology, neurology, cardiology, ophthalmology, endocrinology, gastroenterology, and other related conditions. Oncological disorders involve diseases characterized by the uncontrolled growth and spread of abnormal cells, commonly known as cancer, which can affect various organs and tissues. Virtual biopsy is used for detecting a wide range of cancers, including solid tumors, breast cancer, lung cancer, prostate cancer, colorectal cancer, brain cancer, and others. The imaging technologies utilized in virtual biopsy include magnetic resonance imaging (MRI), computed tomography (CT), X-ray, ultrasound, among others, and are employed by end users such as hospitals, clinics, research institutes, diagnostic centers, and more.
The virtual biopsy market consists of revenues earned by entities by providing services such as imaging diagnostics, artificial intelligence (AI)-based interpretation, biomarker testing, telemedicine services, and three-dimensional (3D) tissue modeling. The market value includes the value of related goods sold by the service provider or included within the service offering. The virtual biopsy market also includes sales of biopsy needle systems, artificial intelligence (AI)-based diagnostic tools, endoscopic systems, and photoacoustic imaging devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Virtual Biopsy Market Characteristics
3. Virtual Biopsy Market Supply Chain Analysis
4. Global Virtual Biopsy Market Trends and Strategies
5. Virtual Biopsy Market Analysis of End Use Industries
7. Global Virtual Biopsy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Virtual Biopsy Total Addressable Market (TAM) Analysis for the Market
9. Virtual Biopsy Market Segmentation
10. Virtual Biopsy Market Regional and Country Analysis
11. Asia-Pacific Virtual Biopsy Market
12. China Virtual Biopsy Market
13. India Virtual Biopsy Market
14. Japan Virtual Biopsy Market
15. Australia Virtual Biopsy Market
16. Indonesia Virtual Biopsy Market
17. South Korea Virtual Biopsy Market
18. Taiwan Virtual Biopsy Market
19. South East Asia Virtual Biopsy Market
20. Western Europe Virtual Biopsy Market
21. UK Virtual Biopsy Market
22. Germany Virtual Biopsy Market
23. France Virtual Biopsy Market
24. Italy Virtual Biopsy Market
25. Spain Virtual Biopsy Market
26. Eastern Europe Virtual Biopsy Market
27. Russia Virtual Biopsy Market
28. North America Virtual Biopsy Market
29. USA Virtual Biopsy Market
30. Canada Virtual Biopsy Market
31. South America Virtual Biopsy Market
32. Brazil Virtual Biopsy Market
33. Middle East Virtual Biopsy Market
34. Africa Virtual Biopsy Market
36. Virtual Biopsy Market Competitive Landscape and Company Profiles
37. Virtual Biopsy Market Other Major and Innovative Companies
40. Virtual Biopsy Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Virtual Biopsy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses virtual biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for virtual biopsy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The virtual biopsy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Target Thrapeutic Areas: Oncological Disorders; Neurological Disorders; Cardiovascular Disorders; Ophthalmological Disorders; Endocrine Disorders; Gastrointestinal Disorders; Other Target Therapeutic Areas2) By Cancer Targeted: Solid Malignancies; Breast Cancer; Lung Cancer; Prostate Cancer; Colorectal Cancer; Brain Cancer; Other Cancer Targeteds
3) By Imaging Technologies: Magnetic Resonance Imaging; Computed Tomography; X-Ray; Ultrasound; Other Imaging Technologies
4) By End Users: Hospitals And Clinics; Research Institutes And Diagnostic Centers; Other End Users
Subsegments:
1) By Oncological Disorders: Lung Cancer; Breast Cancer; Prostate Cancer; Colorectal Cancer; Liver Cancer; Brain Tumors; Other Cancers2) By Neurological Disorders: Alzheimer's Disease; Parkinson's Disease; Multiple Sclerosis; Epilepsy; Brain Injuries; Stroke; Other Neurological Conditions
3) By Cardiovascular Disorders: Coronary Artery Disease; Heart Failure; Arrhythmias; Aortic Aneurysm; Valvular Heart Disease; Myocardial Infarction; Other Cardiovascular Conditions
4) By Ophthalmological Disorders: Age-Related Macular Degeneration; Diabetic Retinopathy; Glaucoma; Retinal Vein Occlusion; Cataracts; Other Eye Disorders
5) By Endocrine Disorders: Diabetes Mellitus; Thyroid Disorders; Adrenal Gland Disorders; Pituitary Gland Disorders; Parathyroid Disorders; Other Endocrine Conditions
6) By Gastrointestinal Disorders: Inflammatory Bowel Disease; Colorectal Polyps; Gastric Ulcers; Liver Cirrhosis; Pancreatic Disorders; Hepatitis; Other Gastrointestinal Conditions
7) By Other Target Therapeutic Areas: Musculoskeletal Disorders; Renal Disorders; Pulmonary Disorders; Hematologic Disorders; Dermatological Disorders; Infectious Diseases; Other Miscellaneous Conditions
Companies Mentioned: Siemens Healthineers AG; GE Healthcare; Canon Medical Systems; Philips Healthcare; Fujifilm Healthcare; Esaote SpA; Samsung Medison; Perspectum Ltd; QUIBIM SL; ImageBiopsy Lab GmbH; Deep Bio Inc; BrainSpec Inc; Oncoustics Inc; AI Metrics LLC; Zebra Medical Vision; Arterys Inc; Aidoc Medical; Viz ai; Subtle Medical; Gleamer AI
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Virtual Biopsy market report include:- Siemens Healthineers AG
- GE Healthcare
- Canon Medical Systems
- Philips Healthcare
- Fujifilm Healthcare
- Esaote SpA
- Samsung Medison
- Perspectum Ltd
- QUIBIM SL
- ImageBiopsy Lab GmbH
- Deep Bio Inc
- BrainSpec Inc
- Oncoustics Inc
- AI Metrics LLC
- Zebra Medical Vision
- Arterys Inc
- Aidoc Medical
- Viz ai
- Subtle Medical
- Gleamer AI
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.79 Billion |
| Forecasted Market Value ( USD | $ 1.23 Billion |
| Compound Annual Growth Rate | 11.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
